CDF之声|阿斯利康董事长雷夫·约翰森：创造来得健康、来得强大、来得加可持续的未来

p>此刻，对有数现代的经济和预见，我们比常规任何时候都更加有期待。阿斯利康全面深化在华整体设计，在杭州、成都、杭州、常州和广州设立5个范围内的总部，每个范围内的总部各定位于一个核心领域，比如，基层智慧保健、数字保健革新等。随着我们位于上海的世界性研发有数现代教育里面心意味着全新升级，我们也将不间断为有数现代患儿造成革新抑制剂，为“有益有数现代”做到更加大杰出贡献。

我期待和大家继续论述并遏制合作。让我们联手用科学和革新为人类、社会及整个地球的“有益”造成无限可能。

谢谢！

I am honoured to speak with you at the China Development Forum today．

On behalf of AstraZeneca， I would like to congratulate China on the extraordinary success of the Winter Olympics， particularly in light of the COVID-19 crisis． You deserve much credit for achieving an exceptional level of COVID-19 control． These achievements not only benefit people in China， but also provide hope to the world as countries aspire to stem the pandemic， rebuild their economy， and return to normal．

To do this， we must work together， across industries and borders， with urgency and one shared goal． To create a healthier， stronger and more sustainable future for all．

Over the last decades， China’s huge transformation has been a catalyst for an ever-thriving healthcare sector． China is AstraZeneca’s second largest country market and we are the largest multinational biopharmaceutical company in the country． We are committed to ensuring that our partnership with China continues to go from strength-to-strength – at the municipal， provincial and central levels．

Our impact in China also impacts patients worldwide． Through the development， manufacturing and distribution of the AstraZeneca/Oxford COVID-19 vaccine， China is playing a critical role in providing greater access and supporting global health efforts．

For example – Wuxi Biologics is one of AstraZeneca’s key suppliers for our vaccine． It is producing the active ingredient for approximately 50% of our supply to COVAX which will be distributed globally． Furthermore， we he transferred our vaccine technology free of charge to BioKangtai in Shenzhen． This enabled almost 30 million doses to be supplied worldwide， including Indonesia． Globally， in 2021 we released for supply over 2.7 billion doses of our COVID-19 vaccine in more than 170 countries． Approximately two-thirds of the doses he gone to low- and lower- income countries．

Furthermore， our long-acting antibody Evusheld for the prevention of COVID-19 has been granted emergency use by the FDA in the U.S． We hope to introduce this in China to benefit patients who are unable to get vaccinated．

We are extremely grateful for China’s partnership and remain committed to ensuring equitable access to Covid-19 vaccine and preventative medicines， a commitment that is shared by the Chinese government．

Looking ahead beyond the pandemic， there is significant opportunity for us to learn and take action to build more resilient and sustainable health systems and economies for a brighter future．

One of the areas in which China is leading the way is the accelerated adoption of innovative technologies that he the potential to transform healthcare delivery and make healthcare more affordable and accessible． AstraZeneca is proud to jointly lead the Smart Healthcare Innovation Centre which supports the implementation of innovative holistic disease management solutions． We he supported over 60 outstanding life science companies to bring to life ideas in our innovation incubation platform iCampus． And we he also supported the development of Yili Internet Hospital in China．

Millions of people in China are now accessing healthcare through technology-based partnerships thanks to the excellent ecosystem created by the country． These are world-class examples of public-private collaboration， and best practices which other countries can replicate to support population health around the world．

Now more than ever， we are confident in China’s economy and future． AstraZeneca has demonstrated this by further deepening our footprint in China by launching 5 regional headquarters in Beijing， Chengdu， Hangzhou， Wuxi and Guangzhou， each focused on key areas including smart primary healthcare and digital healthcare． With our newly upgraded global R&D center in Shanghai， we stand ready to meet Chinese patients’ needs with innovative medicines and make even greater contributions to building a Healthy China．

I look forward to continuing the discussion and collaboration． Together， we can harness the power of science and innovation for the health of people， societies and the planet．

Thank you！

。

扶他林与英太青哪个止痛管用
子宫肌瘤
吃什么可以去暑
小肚子胀
说明书明确写着孕妇可以服用的益生菌有哪些